Biogen speaks

It’s been about a week since Biogen told the world that aducanumab, the treatment for Alzheimer’s disease on which the company staked its future, fared no better than placebo in two large trials.

That news came via a brief press release. Now, $20 billion of lost market cap later, Biogen will get the chance to explain it all in long form.

On Monday, Biogen’s head of R&D will speak at Stifel’s conveniently timed “CNS day.” Michael Ehlers, who joined Biogen from Pfizer in 2016, will presumably delve into the aducanumab disappointment and address the biggest question now facing his company: What are you going to do next?

His presentation starts at noon ET, and you can stream it on Biogen’s website.